Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Clinical Trial Alzheimer's Disease and Cannabis (DAZACANN)

NCT06570928 is registered in ClinicalTrials.gov with Federal University of Latin American Integration as lead sponsor.

NCT NCT06570928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06570928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Use of a Product Containing the Cannabinoids CBD and THC as a Treatment Strategy for Alzheimer's Disease - Clinical Trial Alzheimer's Disease and Cannabis (DAZACANN)
Lead sponsor
Federal University of Latin American Integration
Phase
Phase 2
Overall status
Completed
Start date
August 13, 2024
Completion date
March 27, 2025
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease